Cefminox

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Cefminox
Accession Number
DB09062
Type
Small Molecule
Groups
Approved
Description

Cefminox (INN) is a second-generation cephalosporin antibiotic. It is approved for use in Japan.

Structure
Thumb
Synonyms
  • cefminoxum
  • CMNX
Product Ingredients
IngredientUNIICASInChI Key
Cefminox sodiumYNM4DBJ3N875498-96-3SBIDXLKJYJVQOE-YNJMIPHHSA-M
Cefminox sodium hydrateKZ89N378LQ1351813-81-4QCIJKKRQPRMHOX-IJARWDBPSA-M
International/Other Brands
Meicelin
Categories
UNII
PW08Y13465
CAS number
84305-41-9
Weight
Average: 519.57
Monoisotopic: 519.066459566
Chemical Formula
C16H21N7O7S3
InChI Key
JSDXOWVAHXDYCU-VXSYNFHWSA-N
InChI
InChI=1S/C16H21N7O7S3/c1-22-15(19-20-21-22)33-4-7-3-32-14-16(30-2,13(29)23(14)10(7)12(27)28)18-9(24)6-31-5-8(17)11(25)26/h8,14H,3-6,17H2,1-2H3,(H,18,24)(H,25,26)(H,27,28)/t8-,14-,16+/m1/s1
IUPAC Name
(6R,7S)-7-(2-{[(2S)-2-amino-2-carboxyethyl]sulfanyl}acetamido)-7-methoxy-3-{[(1-methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
SMILES
[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)CSC[C@@H](N)C(O)=O)OC)C(O)=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AcenocoumarolCefminox may increase the anticoagulant activities of Acenocoumarol.
AcetaminophenCefminox may decrease the excretion rate of Acetaminophen which could result in a higher serum level.
Acetylsalicylic acidThe risk or severity of nephrotoxicity can be increased when Cefminox is combined with Acetylsalicylic acid.
AlprazolamCefminox may decrease the excretion rate of Alprazolam which could result in a higher serum level.
AmikacinThe risk or severity of nephrotoxicity can be increased when Cefminox is combined with Amikacin.
AmitriptylineCefminox may decrease the excretion rate of Amitriptyline which could result in a higher serum level.
AmlodipineCefminox may decrease the excretion rate of Amlodipine which could result in a higher serum level.
AmoxicillinCefminox may decrease the excretion rate of Amoxicillin which could result in a higher serum level.
AmphetamineCefminox may decrease the excretion rate of Amphetamine which could result in a higher serum level.
AmpicillinCefminox may decrease the excretion rate of Ampicillin which could result in a higher serum level.
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Drug
D07642
ChemSpider
64286
ChEBI
135817
ChEMBL
CHEMBL1276342
Drugs.com
Drugs.com Drug Page
Wikipedia
Cefminox
ATC Codes
J01DC12 — Cefminox

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.09 mg/mLALOGPS
logP-1.5ALOGPS
logP-3.6ChemAxon
logS-2.7ALOGPS
pKa (Strongest Acidic)1.56ChemAxon
pKa (Strongest Basic)8.82ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count11ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area202.86 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity133.34 m3·mol-1ChemAxon
Polarizability48.92 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as cephamycins. These are compounds containing a the cephalosporin (oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid) nucleus, with an alkyloxy group attached to the C6 carbon atom.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Lactams
Sub Class
Beta lactams
Direct Parent
Cephamycins
Alternative Parents
N-acyl-alpha amino acids and derivatives / Cysteine and derivatives / S-alkyl-L-cysteines / D-alpha-amino acids / Alkylarylthioethers / Dicarboxylic acids and derivatives / 1,3-thiazines / Tetrazoles / Tertiary carboxylic acid amides / Heteroaromatic compounds
show 13 more
Substituents
Cephamycin / N-acyl-alpha amino acid or derivatives / Cysteine or derivatives / S-alkyl-l-cysteine / Alpha-amino acid / Alpha-amino acid or derivatives / D-alpha-amino acid / Aryl thioether / Alkylarylthioether / Meta-thiazine
show 30 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on May 11, 2015 16:10 / Updated on September 21, 2018 00:21